DAXXIFY® is the peptide-engineered,
long-lasting neurotoxin for durable symptom control.1,2*
Stay Updated On Product Availability Read Press Release *Median duration of effect, defined as time from treatment until loss
of ≥80% of the peak effect (change from baseline in TWSTRS total score
averaged across weeks 4 and 6), was 24 weeks with DAXXIFY®
125U and 20.3 weeks with DAXXIFY® 250U. In
patients that requested retreatment prior to the loss of ≥80% of peak
effect, median efficacy remaining was 45% to 54% in ASPEN-1. Median
time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles
1 and 2 in the ASPEN OLS.2-3
DAXXIFY® demonstrates durable symptom relief that extends
beyond the current retreatment interval of 12 weeks.1,2,4-8*
Per the Phase 3 pivotal trial, DAXXIFY® is generally safe
and well tolerated, with no serious treatment-related adverse events
reported.1,2
*Median duration of effect, defined as time from treatment until loss of
≥80% of the peak effect (change from baseline in TWSTRS total score averaged
across weeks 4 and 6), was 24 weeks with DAXXIFY® 125U and 20.3 weeks with
DAXXIFY® 250U. In patients that requested retreatment prior to the loss of
> 80% of peak effect, median efficacy remaining was 45% to 54% in ASPEN-1.
Median time to retreatment was between 16 and 17 weeks in ASPEN-1 and cycles
1 and 2 in the ASPEN OLS.2-3
DAXXIFY® is the only botulinum toxin
engineered with cell-penetrating peptide technology.1,6-10
Proprietary peptide 3D image
Learn more about the unique DAXXIFY® formulation
from:
Conor Gallagher, PhD
VP, Medical Affairs and Scientific Innovation
The ASPEN program
DAXXIFY® demonstrated impressive performance
in the ASPEN-1 pivotal study and the ASPEN open-label study (OLS).2,3
Benefits Verification
A benefits investigation is an important first step to determine how DAXXIFY®
will be covered by a patient's specific health plan.
There are two ways to request a benefits verification.